GlassScriptPhysician profile
Jamine L Shechter
NPI 1992708358
$1,545.40
in general payments reported to CMS, 2019-2025
26 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $101 · 2021: $231 · 2022: $220 · 2023: $351 · 2024: $251 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $438.10 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $101.23 | 2023-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $95.19 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $94.29 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $89.21 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Horizon Therapeutics Plc | $86.51 | 2021-2023 | Tepezza |
| Biohaven Pharmaceutical Holding Company LTD. | $77.25 | 2022 | |
| Alcon Vision LLC | $65.66 | 2022-2025 | Rocklatan |
| Allergan, INC. | $53.80 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.59 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $46.46 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $43.41 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $25.94 | 2021 | |
| Coopervision INC. | $23.65 | 2025 | Myday Contact Lens |
| Eyevance Pharmaceuticals LLC | $23.58 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $23.00 | 2019 | |
| Pfizer INC. | $22.98 | 2023 | |
| Carl Zeiss Meditec, INC. | $22.16 | 2019 | |
| Tearlab Corp | $22.12 | 2019 | |
| Quidel Corporation | $21.36 | 2022 | |
| Amgen INC. | $20.67 | 2024 | Tepezza |
| Abbvie INC. | $20.60 | 2023 | Lumigan, Alphagan P, Vuity |
| Kala Pharmaceuticals, INC. | $19.44 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $18.97 | 2024 | Iyuzeh |
| Omeros Corporation | $17.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamine Shechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.